CFDE Data Portal | Search LOC105377155

	Label	Description
	LOC105377155 Gene (Entity type)	ENSG00000277855 - uncharacterized LOC105377155
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182670 ID3 ID ID1 ID4 ID2 overexpression U-87MG Uppsala RNA Messenger 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE81796 enzalutamide LNCaP C4-2 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113375 DICER1 knockout 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC105377155

ENSG00000277855 - uncharacterized LOC105377155

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 2 human dn

A Gene Set from LINCS

GSE128076 doxycycline HEK293 1 v 0 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 6 human dn

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 2 human dn

A Gene Set from LINCS

GSE182670 ID3 ID ID1 ID4 ID2 overexpression U-87MG Uppsala RNA Messenger 1 v 0 human up

A Gene Set from LINCS

GSE81796 enzalutamide LNCaP C4-2 0 v 2 human dn

A Gene Set from LINCS

GSE113375 DICER1 knockout 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.